Endpoint Surrogacy in First-Line Chronic Lymphocytic Leukemia.
Florian SimonRudy LigtvoetSandra RobrechtPaula CramerNadine KutschMoritz FürstenauValentin GoedeJulia von TresckowPetra LangerbeinsAnna-Maria FinkHenriette HuberEugen TauschChristof SchneiderClemens M WendtnerMatthias RitgenMartin DreylingLothar MüllerLutz JacobaschWerner J HeinzUrsula Vehling-KaiserLiliya SivchevaSebastian BöttcherPeter DregerThomas IllmerMichael GregorPhilipp Bernhard StaberStephan StilgenbauerCarsten Utoft NiemannArnon P KaterKirsten FischerBarbara EichhorstMichael HallekOthman Al-SawafPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Patient-level correlation was confirmed in the setting of targeted therapies while treatment-effect correlation between PFS and OS remains uncertain. MRD response status showed a high treatment-effect correlation with PFS but not OS, with the caveat of a limited number of randomized trials with available MRD data.